Skip to main content

Erratum to:Tetrabenazine as anti-chorea therapy in Huntington Disease: an open-label continuation study

The Original Article was published on 18 December 2009


After publication of this work [1], we became aware of a typographical error. The term dysphagia inadvertently replaced the term dysarthria in two instances. Dysarthria was statistically significantly worsened at week 80 compared to baseline, whereas there was only a statistical trend (p = 0.10) for dysphagia at week 80 compared to baseline. Dysphagia continues to be an issue in patients with Huntington Disease and was reported as an adverse event in this study. Therefore, clinicians who prescribe tetrabenazine should still monitor their patients for worsening swallowing, but the worsening was not statistically different in those who completed this trial. No further studies of tetrabenazine in Huntington Disease have been completed since the publication of this study.

Dysarthria should be replaced for dysphagia in two places and the manuscript should read as follows:

Abstract, page 1:

Results: Parkinsonism and dysarthria scores were significantly increased at week 80 compared to baseline.

Discussion, page 8:

Although parkinsonism and dysarthria were increased in subjects at week 80, this finding was likely a result of the natural progression of disease.

The other uses of the terms dysarthria and dysphagia in the manuscript are correct. We regret the error and any inconvenince it may have caused.


  1. Frank S, Huntington Study Group/TETRA-HD Investigators: Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. BMC Neurol. 2009, 9: 62-10.1186/1471-2377-9-62.

    Article  PubMed  PubMed Central  Google Scholar 

Pre-publication history

Download references

Author information

Authors and Affiliations



Corresponding author

Correspondence to Samuel Frank.

Additional information

The online version of the original article can be found at 10.1186/1471-2377-9-62

Rights and permissions

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and permissions

About this article

Cite this article

Frank, S., Huntington Study Group/TETRA-HD Investigators. Erratum to:Tetrabenazine as anti-chorea therapy in Huntington Disease: an open-label continuation study. BMC Neurol 11, 18 (2011).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: